Little Ironweed (Vernonia cinerea / Cyanthillium cinereum): A Comprehensive Reference
1. Identity: Botanical Names, Taxonomy, and Natural Source
1.1 Current and Historical Botanical Names
Little ironweed, formally described as Vernonia cinerea (L.) Less., carries the synonym Cyanthillium cinereum (L.) H. Rob. and is known as "Sahadevi" in Indian traditional medicine and "Bach dau ong" in Vietnamese traditional medicine. The plant was formerly called Vernonia cinerea, but underwent a taxonomic revision prior to early 2014, with the currently accepted name being Cyanthillium cinereum. Despite this reclassification, the name Vernonia cinerea remains dominant in the scientific literature, and both names are used interchangeably in pharmacological research. Additional synonyms and earlier names include Conyza cinerea and Senecioides cinerea.
The genus Vernonia, within the Asteraceae family, contains the largest number of species in the Vernoniae tribe, with around 1,000 species. The genus was named after William Vernon, a botanist who first identified and classified this diverse group of plants in the late 1600s. The species is a member of the tribe Vernonieae from the family Compositae (Asteraceae). The tribe, traditionally placed in the subfamily Cichorioideae, has recently been proposed for placement in its own subfamily Vernonioideae.
1.2 Common Names Across Languages and Regions
The plant carries numerous common names across different languages: in English it is called "little ironweed" or "purple fleabane"; in Hindi and Sanskrit it is "Sahadevi" (ΰ€Έΰ€Ήΰ€¦ΰ₯ΰ€΅ΰ₯); in Malayalam, it is known as "Poovamkurunthal" or "Poovamkurunnil"; in Tamil it is "Poovamkurunthal"; and in Telugu it is "Sahadevi". In Thai, the plant is called ya dok khao. In Sinhalese, it is known as monara kudumbiya.
1.3 Botanical Description and Natural Distribution
Cyanthillium cinereum is an annual herb growing up to 120 cm (4 feet) tall. It produces flat-topped arrays of numerous flower heads, each with pinkish or purplish disc florets but no ray florets. The genus name Cyanthillium derives from the Greek words kyanos, meaning dark blue (referring to the color of the corollas), and anthyllion, meaning "little flower." Leaves are oblanceolate to obovate, 2 to 6 centimeters long, with pointed or obtuse tips and shallowly toothed margins.
The species is native to tropical Africa and to tropical Asia (including India, Sri Lanka, Indochina, and Indonesia) and has become naturalized in Australia, Mesoamerica, tropical South America, the West Indies, and the US State of Florida. Ecologically, the plant is found in open waste places, dry grassy sites, roadsides, and in plantations of perennial crops.
1.4 Plant Parts Used and Common Preparations
Terpenoids, particularly sesquiterpene lactones, are major secondary constituents of V. cinerea. These, along with steroids, flavonoids, phenolics, and other compounds, have been isolated using different extraction techniques from different plant parts including roots, flowers, stems, and leaves. In practice, preparations used in traditional medicine and research studies include dried whole-plant infusion tea bags, decoctions of roots and stems, fresh juice of roots and leaves, pastilles (oral lozenges), capsule extracts, and topical pastes of leaves and stems.
2. Traditional and Historical Use
2.1 Ayurvedic Medicine (India)
In its ethnobotanical applications, V. cinerea is one of the most widely used species of the Vernonia genus, with a long history of traditional usage in Ayurveda, traditional Asian medicine, and Western herbalism. In Ayurveda, V. cinerea has long been used as a traditional therapy to treat eruptive boils, worms, skin diseases, leprosy, and arthritis. According to the Pharmacopoeia of India, V. cinerea is commonly called "Sahadevi." Sahadevi has been widely utilized for collyrium preparation since ancient times, and eye salve is currently made from the essence of this plant, which is regarded as the best medication for eye conditions in this tradition.
Sahadevi β Vernonia cinerea β is a herb mentioned in the Ayurvedic pharmacopeia for the treatment of fever, localized swelling, wounds, renal calculi, skin diseases, and elephantiasis. In Ayurvedic practice, the paste of the leaves and stem is prepared and applied over wounds and localized swelling; a decoction of the root and stem is administered in a dose of 40β50 ml to treat renal calculi and burning micturition; a cold infusion of the root and stem is given in a dose of 50β60 ml to treat fever caused by indigestion; and the paste of the root is applied externally over areas affected by elephantiasis.
2.2 South and Southeast Asia
In several South Asian nations such as Nepal and Sri Lanka, V. cinerea leaves are used to treat inflammation, wounds, liver function issues, cough, asthma, bronchitis, and gastrointestinal diseases. In some Southeast Asian traditions, the plant has served as a mild analgesic and anti-inflammatory, applied topically to soothe skin irritations or ingested to relieve joint discomfort and menstrual issues. In Vietnam, the plant is used as a natural sedative and analgesic.
In Thailand, V. cinerea has been traditionally used as a diuretic, antipyretic, antitussive, anti-jaundice, anti-hepatitis, tonic, anti-hemorrhoid, and indigestion treatment. The Thai use of the plant for smoking cessation is of particular historical significance: this herb is used in numerous traditional Thai medicines and also for the cessation of smoking; Thailand's National List of Essential Herbal Drugs placed V. cinerea whole plant extract under the indication for smoking cessation.
2.3 Siddha Medicine (South India)
Traditional Siddha Medicine, an Indian traditional medical system, advises using metal-based (mercury, arsenic, copper) formulations for cancer. In the case of any metal toxicities during therapy, Siddha physicians use Vernonia cinerea whole plant kashayam (crude aqueous extract) to reverse the toxic effects.
2.4 Broader African and Pan-Tropical Use
As a perennial herbaceous plant found mainly in tropical areas, particularly in Southeast Asia, South America, and India, various parts of V. cinerea have traditionally been used in folk medicine to treat several diseases such as malaria, fever, and liver diseases. The plant has been demonstrated to possess antipyretic and anti-inflammatory effects, as well as therapeutic activities for alleviating certain gastrointestinal disorders and skin disorders.
3. Key Chemical Constituents and Active Compounds
3.1 Overview of the Phytochemical Profile
V. cinerea has so far yielded about 92 secondary metabolites. The majority of these are sesquiterpene lactones, but triterpenes, flavonoids, steroids, phenolics, and other compounds are present as well. A detailed literature study has revealed that terpenoids, especially sesquiterpene lactones, are major secondary constituents of V. cinerea, with a variety of terpenoids such as C11-terpene lactones, megastigmanes, and triterpenes being identified.
3.2 Sesquiterpene Lactones
Sesquiterpene lactones are considered the most pharmacologically relevant class of compounds in V. cinerea. Four new sesquiterpene lactones have been isolated and characterized: 8Ξ±-(2β²Z-tigloyloxy)-hirsutinolide, 8Ξ±-(2β²Z-tigloyloxy)-hirsutinolide-13-O-acetate, 8Ξ±-(4-hydroxytigloyloxy)-hirsutinolide, and 8Ξ±-hydroxy-13-O-tigloyl-hirsutinolide, along with seven known derivatives, three norisoprenoids, a flavonoid, and a linoleic acid derivative, from a methanol extract of the combined leaves and stems. These hirsutinolide-type sesquiterpene lactones have attracted particular interest for their effects on cancer signaling pathways (see Section 5.3 below).
3.3 Flavonoids and Phenolics
The plant contains alkaloids, flavonoids, and essential oils, which possess antimicrobial properties. The plant contains luteolin-7-mono-beta-D-glucopyranoside along with triterpene compounds such as beta-amyrin acetate and lupeol acetate. The sterols beta-sitosterol, stigmasterol, and alpha-spinasterol are also present.
3.4 Nitrate Content: Relevance to Smoking Cessation
Notably, V. cinerea leaves contain nicotine, which is one proposed reason for its efficacy in smoking cessation β the low levels of plant-derived nicotine may partially substitute for cigarette-derived nicotine while reducing total intake. Additionally, the nitrate content of V. cinerea whole plants has been quantified, with an extraction yield of 15.9 Β± 0.2% and a nitrate content of 1.32 Β± 0.01%, and crude extracts have exhibited good antioxidant activity and a good safety profile.
3.5 Other Identified Compounds
GC-MS analysis of V. cinerea crude aqueous extract has shown the presence of astaxanthin and betulin. The diversity of chemical classes in V. cinerea β spanning terpenoids, flavonoids, sterols, phenolics, and alkaloids β is consistent with the breadth of biological activities reported for the plant.
4. Established and Proposed Mechanisms of Action
4.1 Anti-Inflammatory Mechanisms
The antimicrobial and anti-inflammatory properties of V. cinerea make it a potential candidate for treating various infections and inflammatory diseases. Its anti-inflammatory properties have shown potential for managing inflammatory diseases like arthritis and dermatitis. The sesquiterpene lactone class in particular is widely associated with NF-ΞΊB pathway modulation and inhibition of pro-inflammatory cytokine synthesis across the Asteraceae family, though specific mechanistic studies for V. cinerea are largely confined to in vitro and animal models.
4.2 Anticancer Mechanisms
Cancer studies have shown that V. cinerea has cytotoxicity to cancer cells mainly due to the action of apoptosis. The inhibition of multi-drug resistance transporters (drug efflux pumps) and STAT3-STAT2 phosphorylation has been mentioned as an interesting mechanism. In breast cancer or glioblastoma cells, specific sesquiterpene lactone compounds including 8Ξ±-(2β²Z-tigloyloxy)-hirsutinolide-13-O-acetate reportedly inhibited aberrant STAT3 activity, and these compounds affected the vitality of the U251MG glioblastoma cell line. Normal human epithelial cells were less affected, but human adenocarcinoma cells showed dose-dependent cytotoxicity in response to the dichloromethane fraction of V. cinerea. When combined with anticancer medications, "sesquiterpenoid"-enriched fractions dramatically reduced the functional activity of MDR transporters (ABCB1 and ABCG2) and produced synergistic cytotoxic effects in human adenocarcinoma.
In addition, V. cinerea possesses both cytotoxic and antimetastatic effects on lung cancer cells. These findings are all from preclinical (in vitro and animal) studies; no human clinical trials have evaluated V. cinerea as a cancer treatment.
4.3 Antioxidant Mechanisms
V. cinerea is used for its antioxidant property owing to its superoxide dismutase-like and free radical scavenging activities. Its antioxidant properties make it a potential candidate for preventing and treating oxidative stress-related diseases like cardiovascular disorders and neurodegenerative conditions. These properties are attributed primarily to the phenolic and flavonoid fractions of the plant.
4.4 Renoprotective Mechanisms
Animals exposed to CCl4 display elevated levels of liver marker enzymes in serum, indicating hepatic cell damage. Acute toxicity induced by CCl4 results in enhanced cellular leakage and increased permeability of hepatocyte membranes. However, the elevated activities of liver marker enzymes were suppressed by V. cinerea extract, suggesting that the extract might offer protection against liver damage.
Regarding renal protection specifically, a previous study revealed that V. cinerea can address urinary incontinence. A chloroform extract of V. cinerea leaves exhibited effective hypernatremic, hyperkalemic, and hyperchloremic diuretic effects, while methanol and aqueous extracts showed antidiuretic effect in vivo. At dosages above 62.5 mg/kg, the extracts caused a dose-dependent increase or decrease in urine volume with significant dose-dependent changes in the excretion of Na+ and K+.
4.5 Nicotine-Related Mechanisms (Smoking Cessation)
Supplementation with V. cinerea along with exercise provided benefit related to reduced smoking rate, which may be related to oxidative stress modulation and beta-endorphin levels. The presence of small amounts of plant-derived nicotine in the leaves, along with beta-endorphin-modulating effects, is thought to underlie the smoking cessation properties, though the precise mechanism remains under investigation.
5. Scientific Evidence by Area of Use
5.1 Smoking Cessation β The Best-Studied Clinical Application
Regulatory Status: The herb is used in numerous traditional Thai medicines and for the cessation of smoking; Thailand's National List of Essential Herbal Drugs placed V. cinerea whole plant extract under the indication for smoking cessation.
Meta-Analysis Evidence: Ten RCTs published prior to 2019 were included in one updated meta-analysis. The number of participants in the studies ranged from 35 to 172, with follow-up durations for primary outcomes of 2β12 weeks. This updated meta-analysis found that V. cinerea could significantly improve continuous abstinence rate (CAR) at weeks 2, 4, 8, 12, and 16 (e.g., CAR12: RR=2.56; 95% CI = 1.66, 3.95). Moreover, V. cinerea improved point abstinence rate (PAR) at weeks 2, 4, 8, and 12.
Earlier Meta-Analysis (5 RCTs): A meta-analysis of five clinical trials in 347 smokers concluded that V. cinerea is efficacious for smoking cessation, with the same rate of adverse events β such as dizziness, tongue numbness, or dislike of smell or taste of cigarettes β as placebo, and without any serious adverse event.
Individual RCT β Pastilles (12 Weeks): One study evaluated the smoking cessation effects of V. cinerea in addicted smokers over a longer treatment duration using pastilles, in a randomized double-blinded controlled trial conducted at a community pharmacy. There were 111 eligible participants, 54 of whom were treated with V. cinerea (48.65%) and 57 with placebo (51.35%). Baseline characteristics were comparable. The V. cinerea group had a significantly higher chance of smoking cessation (OR 2.01; 95% CI 1.03β3.92) compared with the placebo group, with no significant side effects in either group. The pastille group showed significantly higher continuous abstinence rate than the placebo group at week 12.
Individual RCT β Comparison with Nortriptyline: One open-label randomized controlled trial compared the efficacy and safety of V. cinerea and nortriptyline for smoking cessation in 84 patients (42 per group). Overall, there was no statistically significant difference in continuous abstinence rate between the two groups (OR 0.68, 95% CI 0.25β1.85, P=0.451). After week 12, the end of treatment, CAR between both groups was not different (44.44% vs 45.95%).
Early Placebo-Controlled RCT (Tea Form): A 24-week, randomized, single-blind, placebo-controlled, parallel trial was conducted at an outpatient smoking cessation clinic in Thailand. A 3-gram crushed dried whole plant was prepared as an infusion tea bag. Sixty-four subjects were equally randomized to receive a 14-day V. cinerea tea taken three times daily or placebo. Primary outcomes were continuous abstinence rate (CAR) and 7-day point prevalence abstinence rate confirmed by urine cotinine. Results showed that the 12-week CARs were 28.1% with V. cinerea versus 12.5% with placebo (p=0.12), not reaching statistical significance.
Pastilles in Low and Moderate Nicotine Dependence: For moderate nicotine dependence, the continuous abstinence rate and point abstinence rate of the V. cinerea pastilles group versus the control group were 42.86% vs. 13.64% (OR=4.75, 95%CI: 1.07β21.14). There was no difference in adverse events between the V. cinerea pastilles group and control group, no serious adverse event was found, and V. cinerea pastilles demonstrated significantly more efficacy than placebo for smoking cessation in moderate nicotine dependence.
Earlier Studies and Duration Dependence: While V. cinerea is a herb that can alleviate nicotine addiction, previous studies examining four-to eight-week treatments using V. cinerea found it to be ineffective, suggesting that the duration of treatment matters for achieving statistically significant results.
Overall Evidence Strength: The evidence base for smoking cessation is the strongest of all clinical applications for this plant, supported by multiple RCTs and two meta-analyses showing consistent positive effect sizes, particularly at 12 weeks and beyond. However, most studies are small, mostly conducted in Thailand, and trials vary in dosage form and duration. Independent large-scale, multi-center trials are needed to confirm these results in broader populations.
5.2 Inflammation and Pain
The anti-inflammatory properties of V. cinerea have shown potential for managing inflammatory diseases like arthritis and dermatitis. Additionally, the plant's analgesic and antipyretic effects suggest potential for pain management and fever reduction. These claims are supported primarily by preclinical (in vitro and animal) data, with validation in cellular models of inflammation. Human clinical evidence for anti-inflammatory or analgesic applications is currently absent from the published literature.
5.3 Cancer (Preclinical Only)
The plant is recognized in Thai traditional medicine and other countries for, among other uses, anticancer activities. Unfortunately, there is little scientific data available for details of the mentioned effects. At the preclinical level, the sesquiterpene lactones isolated from V. cinerea have shown activity against glioblastoma and breast cancer cell lines via STAT3 inhibition, and against lung cancer cells. A review of plants of the Vernonia genus with potential therapeutic uses identified V. cinerea as having the greatest potential within the genus for cancer and inflammation. No human clinical trials on V. cinerea as a cancer treatment have been published. All current cancer-related evidence is in vitro or animal-based and should be characterized as preliminary.
5.4 Renoprotection and Nephrotoxicity Protection
Traditional Siddha physicians use V. cinerea whole plant kashayam (crude aqueous extract) to reverse the toxic effects of metal-based cancer therapies. In preclinical research, the crude aqueous extract and its fractions significantly reversed cisplatin-induced renal damage; animals treated with the extract showed regeneration of 50β75% of proximal tubular cells, and percentage increase in life span of the cisplatin-treated group was 244%, further extended to 379% after crude aqueous extract administration. The crude aqueous extract of V. cinerea reverses cisplatin-induced kidney damage as well as regenerates proximal tubular epithelial cells without compromising the anticancer effect of cisplatin. When the extract was further fractionated, nephroprotective activity was retained, but the beneficial anticancer effect of cisplatin was compromised. This is animal-model data; no human clinical trials have been conducted to test these renoprotective effects.
5.5 Antidiabetic Activity
Animal research has suggested possible antidiabetic effects, supporting some of the traditional uses of the plant. On the basis of results from in vitro and in vivo efficacy and toxicity studies, Vernonia cinerea has potential against cancer and inflammatory conditions β though antidiabetic activity also appears in multiple reviews. No human clinical trials have tested V. cinerea for diabetes or blood glucose management; evidence remains at the preclinical (animal and cell) level.
5.6 Antimicrobial Activity
The plant contains alkaloids, flavonoids, and essential oils which possess antimicrobial properties, making it a promising candidate for treating bacterial and fungal infections. Study results have suggested that V. cinerea does not exhibit any apparent toxicity and may be used as an antimicrobial agent in known dosages, especially in rural communities where conventional drugs are unaffordable. Antimicrobial testing is in vitro; human clinical evidence is absent.
5.7 Antioxidant Activity
Several in vitro and animal studies have identified bioactive compounds such as flavonoids, sesquiterpene lactones, and polyphenols, which may contribute to antioxidant and anti-inflammatory properties. Antioxidant activity is well-documented in laboratory assays, but translation to human health outcomes has not been studied in clinical trials.
6. Body Systems and Health Areas of Association
Based on the totality of traditional use and preclinical and clinical research, Vernonia cinerea has been associated with the following body systems:
- Respiratory system: Used for smoking cessation and as relief for the common cold. Traditional antitussive and anti-asthmatic uses are also documented.
- Urinary/renal system: Reported to address urinary incontinence; a chloroform extract exhibited effective diuretic effects.
- Hepatic system: Traditionally used in folk medicine to treat liver diseases.
- Immune and oncological system: Preclinical anticancer evidence via apoptosis induction and STAT3 inhibition; no clinical evidence.
- Metabolic/endocrine system: Preclinical antidiabetic evidence in animal models.
- Integumentary system (skin): Therapeutic activities for alleviating certain skin disorders documented in both traditional use and preclinical research.
- Musculoskeletal system: Traditional use for arthritis and joint discomfort, supported by anti-inflammatory preclinical evidence.
- Nervous/addiction system: Clinical evidence supporting use in nicotine addiction and smoking cessation.
7. Dosage Forms and Dosages Reported in Studies
The following dosages and dosage forms are drawn directly from published study sources and should not be taken as therapeutic recommendations.
- Infusion tea (whole plant, dried): A 3-gram crushed dried whole plant was prepared in an infusion tea bag; sixty-four subjects were randomized to receive V. cinerea tea taken three times daily for 14 days.
- Pastilles (oral lozenges): Previous studies have mostly focused on 2β4-week treatments with various forms of V. cinerea including infusion tea, lozenges, and capsules; one study developed a 12-week treatment with V. cinerea pastilles.
- Root and stem decoction (Ayurvedic): A decoction of the root and stem is administered in a dose of 40β50 ml to treat renal calculi and burning micturition.
- Cold infusion (Ayurvedic): A cold infusion prepared from the root and stem of Sahadevi is given in a dose of 50β60 ml to treat fever caused by indigestion.
- Fresh juice (Ayurvedic): Fresh juice is used at a dose of 10β20 ml.
- Preclinical dosing (animal studies): In subacute toxicity studies, mice were treated at 50 or 100 mg/kg body weight of ethyl acetate extract consecutively for 28 days.
- Acute toxicity dose (animal studies): For acute toxicity studies, female mice were treated with a single oral dose of 2,000 mg/kg body weight.
8. Safety Considerations
8.1 Acute Toxicity
The methanol extract of V. cinerea, which exhibited antimicrobial activity, was tested for toxicity. In an acute toxicity study using mice, the median lethal dose (LD50) of the extract was greater than 2,000 mg/kg, and no pathological changes were found in macroscopic examination by necropsy of mice treated with the extract. Brine shrimp test LC50 values were 3.87 mg/mL at 6 hours and 2.72 mg/mL at 24 hours, exhibiting no significant toxicity. The methanol extract of V. cinerea did not produce toxic effects in mice and brine shrimp.
8.2 Subacute Toxicity
No mortality or toxic effects were observed in the acute study at 2,000 mg/kg. Repeated dosage of ethyl acetate extract at 50 mg/kg body weight for 28 days did not impart any adverse effects in any of the haematological, biochemical, or histopathological parameters assessed.
8.3 Adverse Events Reported in Human Clinical Trials
A meta-analysis of five clinical trials in 347 smokers concluded that V. cinerea is efficacious for smoking cessation with the same rate of adverse events β including dizziness, tongue numbness, or dislike of smell or taste of cigarettes β as placebo, without any serious adverse event. In clinical trials evaluating pastilles, no serious adverse event was found.
8.4 Solvent-Dependent and Dose-Dependent Effects on Kidney and Electrolytes
The chloroform extract of V. cinerea leaves exhibited diuretic effects (increasing urine volume), whereas methanol and aqueous extracts showed antidiuretic effects in vivo. At dosages above 62.5 mg/kg, the extracts caused dose-dependent changes in urine volume and in the excretion of Na+ and K+. This solvent-dependent, dose-dependent polarity of effect on renal electrolyte handling represents a meaningful safety consideration, as the route and form of preparation significantly affects the physiological outcome.
8.5 Important Limitations of Available Safety Data
Large-scale, well-controlled clinical trials are still needed to confirm the efficacy and safety of little ironweed in humans. Safety data from human clinical trials are limited mainly to smoking cessation studies conducted in Thailand, which have uniformly reported no serious adverse events but have not been powered or designed to detect rare adverse effects. Long-term safety data in humans remain unavailable. The presence of sesquiterpene lactones, a class known for potential allergenicity in susceptible individuals (particularly those with Asteraceae family sensitivities), warrants attention, though this specific concern has not been formally studied for V. cinerea in clinical settings.
References
Go back